Chapter 8: Pharmacogenomics

Chapter 8: Pharmacogenomics

Complete Chapter Questions With Answers

Sample Questions Are Posted Below

Multiple Choice

Identify the choice that best completes the statement or answers the question.

____ 1. Genetic polymorphisms account for differences in metabolism, including:

A.	Poor metabolizers (PMs) who lack a working enzyme
B.	Intermediate metabolizers (IMs) who have one working, wild-type allele and one mutant allele
C.	Extensive metabolizers (EMs), with two normally functioning alleles
D.	All of the above

____ 2. Up to 21% of Asians are ultra-rapid 2D6 metabolizers, leading to:

A.	A need to monitor drugs metabolized by 2D6 for toxicity
B.	Increased dosages needed of drugs metabolized by 2D6, such as the SSRIs
C.	Decreased conversion of codeine to morphine by CYP 2D6
D.	The need for lowered dosages of drugs, such as beta blockers

____ 3. Rifampin is a nonspecific CYP450 inducer that may:

A.	Lead to toxic levels of rifampin and must be monitored closely
B.	Cause toxic levels of drugs, such as oral contraceptives, when co-administered
C.	Induce the metabolism of drugs, such as oral contraceptives, leading to therapeutic failure
D.	Cause nonspecific changes in drug metabolism

____ 4. Inhibition of P-glycoprotein by a drug such as quinidine may lead to:

A.	Decreased therapeutic levels of quinidine
B.	Increased therapeutic levels of quinidine
C.	Decreased levels of a co-administered drug, such as digoxin, that requires P-glycoprotein for absorption and elimination
D.	Increased levels of a co-administered drug, such as digoxin, that requires P-glycoprotein for absorption and elimination

Answer Section

MULTIPLE CHOICE

Additional information